Navigation Links
Serina Therapeutics Awarded Patent for Its Core Polymer Drug Delivery Technology
Date:5/20/2011

HUNTSVILLE, Ala., May 20, 2011 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology.  The patent entitled "Polyoxazoline and compositions comprising the same" (U.S. Patent No. 7,943,141) covers the synthesis and composition of polyoxazolines for the delivery of different drug molecules.      

The patent represents years of groundbreaking research in the development of safe polyoxazoline polymers for drug delivery.  It is the first of many patents that Serina has applied for.  "This patent award validates our invention and design of a novel drug delivery platform and allows Serina the opportunity to advance some of its proprietary ideas towards full development and eventually commercialization," said Dr. Michael D. Bentley, Chief Scientific Officer and cofounder of the company. "We are now in a position to build a strong pipeline of polymer therapeutic molecules."  

About Serina

Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com

Media Contact:  Karen Petersen, 256-327-9434


'/>"/>
SOURCE Serina Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
2. Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics
3. Regency Therapeutics and Daiichi Sankyo Announce Launch and Commercial Availability of SPRIX® (ketorolac tromethamine) Nasal Spray
4. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
5. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
6. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
7. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
8. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
9. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
10. Echo Therapeutics Expands Into New Headquarters in Philadelphia
11. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
Breaking Medicine Technology:
(Date:6/28/2017)... , ... June 28, 2017 , ... With the onset of long work hours and ... fractures due to falls at work and at home will only continue to grow unless ... are not following proper safety procedures, a fall at work or home can lead to ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... technology makes it possible to see through objects, has announced the winners of ... consumer apps with its fully programmable, Raspberry Pi-enabled 3D sensor, Walabot . ...
(Date:6/28/2017)... ... , ... As we celebrate our nation’s independence, many Americans will gather around ... time to celebrate National Hot Dog Month. The National Hot Dog and Sausage ... 4th alone and while they enjoy many different kinds of hot dogs, research commissioned ...
(Date:6/28/2017)... ... 2017 , ... Quorum Health announced that Robert A. Vento has been appointed ... Maher was promoted to COO of QHR. , A national search was ... and CEO in December 2016. , “I’m pleased to announce these ...
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company ... in employee engagement. Omaha-based C&A Industries, a national leader in staffing and ... in North America for 2017. The annual award, issued by Achievers, ...
Breaking Medicine News(10 mins):